Fasenra

Fasenra

Manufacturer:

AstraZeneca

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Benralizumab
Indications/Uses
Add-on maintenance treatment in adult patients w/ severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.
Dosage/Direction for Use
SC Adult 30 mg inj every 4 wk for the 1st 3 doses, then every 8 wk thereafter.
Contraindications
Special Precautions
Not for treatment of acute asthma exacerbation. Uncontrolled or worsened asthma after initiation of treatment. Not recommended to abruptly discontinue corticosteroids after Fasenra initiation. Discontinue use in the event of a hypersensitivity reaction. Patients w/ known helminth infections; treat preexisting helminth infections before initiation therapy. Discontinue use if helminthic infection occurs & patients do not respond to anthelmintics, while receiving Fasenra treatment. Avoid use during pregnancy. Lactation. Childn 5-11 yr.
Adverse Reactions
Headache; pharyngitis; pyrexia, inj site reactions; hypersensitivity reactions.
ATC Classification
R03DX10 - benralizumab ; Belongs to the class of other systemic drugs used in the treatment of obstructive airway diseases.
Presentation/Packing
Form
Fasenra soln for inj 30 mg/mL
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in